THX PHARMA SACA (ALTHX.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALTHX - FR0013286259 - Common Stock
ALTHX.PA Key Statistics, Chart & Performance
The current stock price of ALTHX.PA is 2.03 EUR. In the past year, price increased by 241.75%.
ALTHX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 11.13 | 205.49B | ||
| SNW.DE | SANOFI | 11.11 | 205.06B | ||
| 1SAN.MI | SANOFI | 10.89 | 201.12B | ||
| MRK.DE | MERCK KGAA | 15.15 | 56.17B | ||
| UCB.BR | UCB SA | 39.38 | 49.17B | ||
| UNC.DE | UCB SA | 39.33 | 49.11B | ||
| BAYN.DE | BAYER AG-REG | 7.28 | 38.21B | ||
| 1BAYN.MI | BAYER AG-REG | 7.28 | 38.20B | ||
| IPN.PA | IPSEN | 12.67 | 10.90B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 25.27 | 10.41B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 106.73 | 9.88B | ||
| VIRP.PA | VIRBAC SA | 20.96 | 3.05B |
Related stock screener links
About ALTHX.PA
Company Profile
Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 10 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Company Info
THX PHARMA SACA
60, Avenue Rockefeller - Pepiniere Laennec
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 12
Phone: 33188897031
THX PHARMA SACA / ALTHX.PA FAQ
What does THX PHARMA SACA do?
Theranexus SA engages in the design and development of drug candidates affecting the interaction between neurons and glial cells. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 10 full-time employees. The company went IPO on 2017-10-30. The firm is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The firm's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Can you provide the latest stock price for THX PHARMA SACA?
The current stock price of ALTHX.PA is 2.03 EUR. The price decreased by -2.4% in the last trading session.
Does THX PHARMA SACA pay dividends?
ALTHX.PA does not pay a dividend.
What is the ChartMill rating of THX PHARMA SACA stock?
ALTHX.PA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Would investing in THX PHARMA SACA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALTHX.PA.
ALTHX.PA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ALTHX.PA. When comparing the yearly performance of all stocks, ALTHX.PA is one of the better performing stocks in the market, outperforming 98.85% of all stocks.
ALTHX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALTHX.PA. Both the profitability and financial health of ALTHX.PA have multiple concerns.
ALTHX.PA Financial Highlights
Over the last trailing twelve months ALTHX.PA reported a non-GAAP Earnings per Share(EPS) of -0.36. The EPS increased by 5.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.91% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALTHX.PA Forecast & Estimates
9 analysts have analysed ALTHX.PA and the average price target is 4.51 EUR. This implies a price increase of 122.23% is expected in the next year compared to the current price of 2.03.